ClinicalTrials.gg
CompletedNCT03223337Updated Sep 4, 2019Results posted

Daprodustat Hepatic Impairment Study

A Phase 1 interventional study of Daprodustat (GSK1278863) in Anaemia, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-04.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
21st of 30
37 · median 76
Started
2017
with 3 others
Phase 1
10 of 30
none open now
Registered
21st of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 21st largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 21st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

Daprodustat (GSK1278863), is a small molecule currently in development for the treatment of anemia of chronic kidney disease (CKD). Results of the earlier studies shows that liver is involved in the clearance of Daprodustat and hence, hepatic impairment can affect Daprodustat levels in the body. This single dose study will assess the effect of liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD) of daprodustat. The study will be conducted in two parts, Part 1 will include subjects with moderate hepatic impairment and matched healthy control subjects whereas Part 2 will include subjects will either mild or severe hepatic impairment and matched healthy control subjects. Approximately 8 subjects will be included in each of the group and all subjects will receive 6 milligram (mg) of daprodustat as a single oral dose in the fasted state. Total duration of participation in the study for a subject will be up to 7 weeks.

03

Conditions studied

  • Anaemia

Browse trials for

Keywords

  • GSK1278863
  • Daprodustat
  • Healthy control
  • Single dose
  • Hepatic Impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

For all subjects:

  • Subject must be at least 18 years of age inclusive, at the time of signing the .
  • values at screening \<=16.0 gram per deciliter (g/dL) for males and \<=14.0 g/dL for females.
  • Body weight >=45 kilograms (kg) and (BMI) within the range 18-40 kg per meter square (kg/m\^2) (inclusive).
  • Male or female subjects will be included. A female subject is eligible to participate if she is not breastfeeding, and at least one of the following applies: Not pregnant as confirmed by two pregnancy tests; Not a woman of (WOCBP); For WOCBP that are currently utilizing a highly-effective method prior to enrolment, agrees to follow the contraceptive guidance during the treatment period to the follow-up visit.
  • Capable of giving signed informed consent form.

Additional inclusion criteria for Hepatically-Impaired subjects:

  • Subjects in Part 1 with Moderate Hepatic Impairment Only (Cohort 1): Is considered to have moderate hepatic impairment (of any etiology) and has been clinically stable for at least 1 month prior to screening. To be classified as having moderate hepatic impairment, subjects must have a (Class B) score of 7-9 AND previous confirmation of liver cirrhosis by liver or other medical imaging technique (including laparoscopy, computerized tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasonography) associated with an unambiguous medical history (such as evidence of portal hypertension).
  • Subjects in Part 2 with Mild OR Severe Hepatic Impairment Only (Cohort 3; if conducted): Is considered to have mild or severe hepatic impairment (of any etiology) and has been clinically stable for at least 1 month prior to screening. To be classified as having mild OR severe hepatic impairment, subjects must have: classified as having mild hepatic impairment, subjects must have a Child- Pugh (Class A) score of 5-6 AND previous confirmation of chronic liver disease by liver biopsy or other medical imaging technique (including laparoscopy, CT scan, MRI or ultrasonography) associated with an unambiguous medical history (such as evidence of portal hypertension); classified as having severe hepatic impairment, subjects must have Child- Pugh (Class C) score of 10-13 AND previous confirmation of chronic liver disease by liver biopsy or other medical imaging technique (including laparoscopy, CT scan, MRI or ultrasonography) associated with an unambiguous medical history (such as evidence of portal hypertension).
  • Supplemental inclusion criteria for ALL hepatically-impaired subjects: Chronic (>6 months), stable (no acute episodes of illness due to deterioration in hepatic function within the previous 1 month prior to screening) hepatic impairment due to any etiology. Subjects must also remain stable throughout the Screening period. Assessment of the stability of the subjects hepatic function will be determined by the investigator.

Additional inclusion criteria for healthy control subjects:

  • Healthy control subjects will be matched for age +/-10 years to subjects in the respective hepatic impairment cohort but must also be at least 18 years of age inclusive, at the time of signing the informed consent.
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator and/or the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Healthy control subjects will be matched for BMI +/-15% to subjects in the respective hepatic impairment cohort but must also remain in the range of body weight >=45 kg and BMI within the range 18-38 kg/m\^2 (inclusive).

Exclusion Criteria:

For all subjects:

  • corrected for heart rate according to Fridericia's formula (QTcF) >500 milliseconds (msec).
  • Recent history of deep vein thrombosis, pulmonary embolism or other thrombosis related condition. Any prior medical history in these areas will be reviewed and approved by the PI and the sponsor's Medical Monitor on a case by case basis as needed.
  • Myocardial infarction or acute coronary syndrome, stroke or within the 12 weeks prior to enrollment.
  • Subjects with a pre-existing condition (other than liver disease) interfering with normal gastrointestinal anatomy or motility that could interfere with the absorption, metabolism, and/or excretion of daprodustat.
  • Subjects that have undergone cholecystectomy within the past 3 months.
  • Subjects with chronic inflammatory joint disease (example, scleroderma, systemic lupus erythematosis, rheumatoid arthritis).
  • History of within the prior 2 years or known kidney mass >3 centimeter (cm) (end stage renal disease subjects with impairment only) OR currently receiving treatment for cancer. ONLY exception is localized squamous cell or basal cell carcinoma of the skin definitively treated 12 weeks prior to enrollment.
  • Class IV heart failure, as defined by the (NYHA) functional classification system.
  • Current enrolment or past participation (i.e., administration of last dose of study treatment) within the last 30 days (or 5 half-lives, whichever is longer) before Day 1 in this or any other clinical study involving an investigational study treatment or any other type of medical research.

Exclusion criteria for Hepatically-Impaired subjects:

  • Present of 8 times (ULN) elevations in (AST), Alanine aminotransferase (ALT), or .
  • Subjects with any other medical condition which, in the judgment of the investigator and Medical Monitor, could jeopardize the integrity of the data derived from that subject or the safety of the subject.
  • Subjects with advanced ascites (Grade 3).
  • Subjects with encephalopathy as judged by the investigator or significant Central Nervous System (CNS) disease (example dementia, or seizures) which the investigator considers will interfere with the informed consent, conduct, completion, or results of this trial or constitutes an unacceptable risk to the subject.
  • Subjects with functional Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.
  • Presence of hepatopulmonary or hepatorenal syndrome.
  • Presence of primarily cholestatic liver diseases.
  • History of liver transplantation.
  • Subjects with signs of active infection, including active spontaneous bacterial peritonitis.
  • Subjects with unstable cardiac function or subjects with hypertension whose blood pressure is not controlled (based on the investigator's discretion).
  • Diabetic subjects whose diabetes is not controlled (based on the investigator's discretion).

Exclusion criteria for healthy control subjects:

  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Presence of surface antigen (HBsAg) at screening or Positive antibody test result at screening or within 3 months before the first dose of study treatment.
  • Positive pre-study drug/alcohol screen.
  • Positive (HIV) antibody test.
  • Regular use of known drugs of abuse.
  • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >14 drinks. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits. One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Subjects with moderate hepatic impairment: Part 1

    Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.

    Drug: Daprodustat (GSK1278863)

  • Active comparator
    Matched Healthy controls: Part 1

    Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.

    Drug: Daprodustat (GSK1278863)

  • Experimental
    Subjects with either mild or severe hepatic impairment: Part 2

    Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.

    Drug: Daprodustat (GSK1278863)

  • Active comparator
    Matched healthy controls: Part 2

    Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.

    Drug: Daprodustat (GSK1278863)

Interventions

  • Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  2. Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  3. Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  4. Part 2: Percentage AUCex of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  5. Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  6. Part 2: AUC (0-t) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  7. Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  8. Part 2: Cmax of GSK1278863 and Its Metabolites.

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  9. Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  10. Part 2: T1/2 of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  11. Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  12. Part 2: Tmax of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose

  13. Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: 3 hours, 12 hours and 24 hours post-dose

  14. Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: 3 hours, 12 hours and 24 hours post-dose

  15. Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.

    Time frame: 3 hours, 12 hours and 24 hours post-dose

  16. Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.

    Time frame: 3 hours, 12 hours and 24 hours post-dose

Secondary outcomes

  1. Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863

    Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  2. Part 2: Cmax, EPO Following Administration of GSK1278863

    Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  3. Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863

    Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  4. Part 2: Tmax, EPO Following Administration of GSK1278863

    Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  5. Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863

    Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  6. Part 2: AUC (0-t, EPO) Following Administration of GSK1278863

    Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

    Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose

  7. Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.

    Time frame: Up to 16 days

  8. Part 2: Number of Participants With AEs and SAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.

    Time frame: Up to 16 days

  9. Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

    Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 grams per liter (g/L) for hemoglobin, \<3 or \>20 x10\^9 cells per liter (cells/L) for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given \[e.g.\], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

    Time frame: Baseline (Screening) and up to Day 16

  10. Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline

    Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 g/L for hemoglobin, \<3 or \>20 x10\^9 cells/L for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

    Time frame: Baseline (Screening) and up to Day 16

  11. Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline

    Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 millimoles/L(mmol/L) (calcium), \<3 or \>9mmol/L(glucose), \>=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase \[ALT\]), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L(aspartate aminotransferase \[AST\]), \>=1.5 times ULN micromoles/L (µmol/L)(bilirubin), \<3 or \>5.5mmol/L(potassium), and \<130 or \>150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

    Time frame: Baseline (Screening) and up to Day 16

  12. Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline

    Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 mmol/L (calcium), \<3 or \>9mmol/L (glucose), \>=2 times ULN U/L (ALT), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L (AST), \>=1.5 times ULN µmol/L (bilirubin), \<3 or \>5.5 mmol/L (potassium), and \<130 or \>150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

    Time frame: Baseline (Screening) and up to Day 16

  13. Part 1: Number of Participants With Abnormal Urinalysis Findings

    Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.

    Time frame: Up to Day 16

  14. Part 2: Number of Participants With Abnormal Urinalysis Findings

    Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.

    Time frame: Up to Day 16

07

Results

Posted Sep 4, 2019

Participant flow

This was a two part study in adults with moderate (Part 1) and potentially mild (Part 2) hepatic impairment and matched, healthy control participants with normal hepatic function. This study was conducted at two centers in the United States of America (USA).

Part 1 (Up to 16 Days)
Participant flow — Part 1 (Up to 16 Days)
MilestonePart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Started8800
Completed8800
Not completed0000
Part 2 (Up to 16 Days)
Participant flow — Part 2 (Up to 16 Days)
MilestonePart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Started00129
Completed00129
Not completed0000

Outcome measures

PrimaryPart 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Hour*nanogram per milliliter
Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites
Hour*nanogram per milliliterPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK1278863296.2407 ± 111.1148.3225 ± 31.7
GSK2391220 (M2)77.6352 ± 56.947.1340 ± 30.9
GSK2487818 (M4)47.5557 ± 67.428.9896 ± 30.3
GSK2506102 (M5)16.8212 ± 43.911.2658 ± 29.4
GSK2506104 (M3)NA ± NANA ± NA
GSK2531398 (M6)33.9398 ± 49.220.9224 ± 27.7
GSK2531401 (M13)52.0606 ± 34.039.6044 ± 32.1
Statistical analysis
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric least square(ls) mean: 1.9973 · 90% CI 1.1063 to 3.6057Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.6471 · 90% CI 1.1267 to 2.4079Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.6404 · 90% CI 1.0744 to 2.5048Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.4931 · 90% CI 1.0876 to 2.0498Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.6222 · 90% CI 1.1594 to 2.2696Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.3145 · 90% CI 0.9896 to 1.7462Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 2: AUC (0-infinity) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Hour*nanogram per milliliter
Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites
Hour*nanogram per milliliterPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK1278863299.8773 ± 39.9205.7559 ± 37.2
GSK2391220 (M2)91.3799 ± 44.747.1647 ± 26.9
GSK2487818 (M4)63.6211 ± 40.131.7637 ± 28.4
GSK2506102 (M5)19.4020 ± 36.611.3374 ± 26.7
GSK2506104 (M3)91.7692 ± 41.050.1154 ± 28.3
GSK2531398 (M6)41.4666 ± 31.221.0066 ± 23.5
GSK2531401 (M13)46.7001 ± 66.531.9797 ± 40.9
Statistical analysis
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.4574 · 90% CI 1.0350 to 2.0523Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.9375 · 90% CI 1.3919 to 2.6968Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.8312 · 90% CI 1.3342 to 2.5133Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 2.0030 · 90% CI 1.4654 to 2.7378Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.7113 · 90% CI 1.2818 to 2.2847Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.9740 · 90% CI 1.5365 to 2.5360Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.4603 · 90% CI 0.9081 to 2.3484Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Mean · Percentage of AUCex
Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites
Percentage of AUCexPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK12788630.0463 ± 0.039710.0486 ± 0.03445
GSK2391220 (M2)0.1919 ± 0.141640.4176 ± 0.38893
GSK2487818 (M4)0.5756 ± 0.895640.6763 ± 0.61031
GSK2506102 (M5)0.6147 ± 0.174032.1559 ± 2.01781
GSK2506104 (M3)NA ± NANA ± NA
GSK2531398 (M6)0.2598 ± 0.100040.3689 ± 0.26189
GSK2531401 (M13)0.2983 ± 0.271410.2787 ± 0.15617
PrimaryPart 2: Percentage AUCex of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Mean · Percentage of AUCex
Part 2: Percentage AUCex of GSK1278863 and Its Metabolites
Percentage of AUCexPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK12788630.1148 ± 0.260350.0601 ± 0.06032
GSK2391220 (M2)0.2943 ± 0.326980.8105 ± 1.60084
GSK2487818 (M4)0.2584 ± 0.307270.9054 ± 0.89147
GSK2506102 (M5)0.5138 ± 0.228591.5924 ± 1.69300
GSK2506104 (M3)0.2565 ± 0.283820.6875 ± 1.33005
GSK2531398 (M6)0.2915 ± 0.253500.9412 ± 0.94415
GSK2531401 (M13)0.2327 ± 0.233380.5256 ± 0.46352
PrimaryPart 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Hour*nanogram per milliliter
Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites
Hour*nanogram per milliliterPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK1278863296.1035 ± 111.2148.2504 ± 31.8
GSK2391220 (M2)77.4861 ± 57.046.9368 ± 31.0
GSK2487818 (M4)47.2803 ± 67.728.7930 ± 30.6
GSK2506102 (M5)16.7177 ± 43.911.0208 ± 30.9
GSK2506104 (M3)NA ± NANA ± NA
GSK2531398 (M6)33.8516 ± 49.320.8451 ± 27.8
GSK2531401 (M13)51.9052 ± 34.139.4939 ± 32.3
Statistical analysis
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.9973 · 90% CI 1.1061 to 3.6066Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.6509 · 90% CI 1.1285 to 2.4150Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.6421 · 90% CI 1.0732 to 2.5125Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.5169 · 90% CI 1.0994 to 2.0930Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.6240 · 90% CI 1.1599 to 2.2736Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.3143 · 90% CI 0.9887 to 1.7470Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 2: AUC (0-t) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Hour*nanogram per milliliter
Part 2: AUC (0-t) of GSK1278863 and Its Metabolites
Hour*nanogram per milliliterPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK1278863299.5322 ± 39.9205.6322 ± 37.2
GSK2391220 (M2)91.1105 ± 44.946.7771 ± 27.9
GSK2487818 (M4)63.4564 ± 40.331.4750 ± 29.0
GSK2506102 (M5)19.3023 ± 36.811.1555 ± 27.1
GSK2506104 (M3)91.5334 ± 41.249.7669 ± 29.2
GSK2531398 (M6)41.3456 ± 31.420.8080 ± 24.0
GSK2531401 (M13)46.5914 ± 66.831.8113 ± 41.3
Statistical analysis
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.4566 · 90% CI 1.0344 to 2.0513Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.9478 · 90% CI 1.3935 to 2.7224Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.8392 · 90% CI 1.3350 to 2.5340Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 2.0161 · 90% CI 1.4711 to 2.7630Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.7303 · 90% CI 1.2932 to 2.3151Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.9870 · 90% CI 1.5426 to 2.5594Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.4646 · 90% CI 0.9086 to 2.3609Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites
Nanogram per milliliterPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK1278863139.705 ± 108.870.607 ± 51.7
GSK2391220 (M2)13.046 ± 46.210.199 ± 28.7
GSK2487818 (M4)10.022 ± 55.08.025 ± 28.5
GSK2506102 (M5)2.650 ± 34.62.245 ± 23.0
GSK2506104 (M3)NA ± NANA ± NA
GSK2531398 (M6)5.946 ± 41.74.672 ± 24.1
GSK2531401 (M13)7.411 ± 35.07.120 ± 28.0
Statistical analysis
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.9786 · 90% CI 1.0557 to 3.7084Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.2791 · 90% CI 0.9241 to 1.7705Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.2487 · 90% CI 0.8675 to 1.7974Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.1802 · 90% CI 0.9165 to 1.5197Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.2726 · 90% CI 0.9520 to 1.7012Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.0409 · 90% CI 0.7927 to 1.3668Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 2: Cmax of GSK1278863 and Its Metabolites.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Part 2: Cmax of GSK1278863 and Its Metabolites.
Nanogram per milliliterPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK1278863113.232 ± 42.6112.142 ± 35.7
GSK2391220 (M2)15.792 ± 40.88.846 ± 40.0
GSK2487818 (M4)13.614 ± 34.77.723 ± 35.6
GSK2506102 (M5)3.241 ± 35.71.975 ± 33.4
GSK2506104 (M3)15.475 ± 38.88.926 ± 37.9
GSK2531398 (M6)7.333 ± 28.24.010 ± 31.7
GSK2531401 (M13)6.791 ± 65.55.081 ± 43.4
Statistical analysis
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.0097 · 90% CI 0.7122 to 1.4316Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.7852 · 90% CI 1.2498 to 2.5498Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.7337 · 90% CI 1.2343 to 2.4353Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.7628 · 90% CI 1.2898 to 2.4092Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.6413 · 90% CI 1.2055 to 2.2347Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.8289 · 90% CI 1.3992 to 2.3904Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.3367 · 90% CI 0.8288 to 2.1557Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Hours
Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites
HoursPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK12788633.9867 ± 33.24.4054 ± 29.8
GSK2391220 (M2)4.1830 ± 26.95.6415 ± 37.1
GSK2487818 (M4)2.6559 ± 38.33.6385 ± 83.8
GSK2506102 (M5)3.1966 ± 23.42.7314 ± 36.4
GSK2506104 (M3)NA ± NANA ± NA
GSK2531398 (M6)3.1287 ± 26.03.2641 ± 56.3
GSK2531401 (M13)3.9432 ± 22.83.9414 ± 33.1
Statistical analysis
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 0.9050 · 90% CI 0.6900 to 1.1869Ratio of Geometric LS Mean for GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 0.7415 · 90% CI 0.5617 to 0.9787Ratio of Geometric LS Mean for GSK2391220 (M2) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 0.7299 · 90% CI 0.4387 to 1.2145Ratio of Geometric LS Mean for GSK2487818 (M4) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.1703 · 90% CI 0.9000 to 1.5219Ratio of Geometric LS Mean for GSK2506102 (M5) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 0.9585 · 90% CI 0.6664 to 1.3786Ratio of Geometric LS Mean for GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Ratio of geometric ls mean: 1.0004 · 90% CI 0.7833 to 1.2778Ratio of Geometric LS Mean for GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 2: T1/2 of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Geometric mean · Hours
Part 2: T1/2 of GSK1278863 and Its Metabolites
HoursPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK12788634.5251 ± 27.44.2792 ± 38.7
GSK2391220 (M2)4.8118 ± 21.24.7439 ± 49.6
GSK2487818 (M4)4.1059 ± 47.83.0578 ± 88.9
GSK2506102 (M5)3.4087 ± 30.83.3108 ± 56.7
GSK2506104 (M3)4.6675 ± 20.24.4967 ± 45.0
GSK2531398 (M6)3.8096 ± 38.42.9947 ± 57.1
GSK2531401 (M13)4.2869 ± 21.23.5510 ± 34.2
Statistical analysis
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.0574 · 90% CI 0.7876 to 1.4197Ratio of Geometric LS Mean for GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.0143 · 90% CI 0.7332 to 1.4032Ratio of Geometric LS Mean for GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.0380 · 90% CI 0.7695 to 1.4002Ratio of Geometric LS Mean for GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.3427 · 90% CI 0.7635 to 2.3615Ratio of Geometric LS Mean for GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.0296 · 90% CI 0.6996 to 1.5151Ratio of Geometric LS Mean for GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.2721 · 90% CI 0.8409 to 1.9245Ratio of Geometric LS Mean for GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Ratio of geometric ls mean: 1.2072 · 90% CI 0.9398 to 1.5508Ratio of Geometric LS Mean for GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Median · Hours
Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites
HoursPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK12788631.50 (1.0 to 3.0)2.00 (1.0 to 3.0)
GSK2391220 (M2)3.00 (3.0 to 6.0)3.50 (2.0 to 4.0)
GSK2487818 (M4)3.00 (2.0 to 6.0)3.00 (1.5 to 4.0)
GSK2506102 (M5)3.50 (3.0 to 6.0)4.00 (2.0 to 4.0)
GSK2506104 (M3)NA (NA to NA)NA (NA to NA)
GSK2531398 (M6)3.50 (3.0 to 6.0)3.50 (2.0 to 4.0)
GSK2531401 (M13)4.00 (3.0 to 6.0)4.00 (3.0 to 6.0)
Statistical analysis
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.6822 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 0.50Median Difference in GSK1278863 (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.5767 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2391220 (M2)(Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.5880 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.50Median Difference in GSK2487818 (M4)(Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.7716 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2506102 (M5)(Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.4093 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.50 · 90% CI -1.00 to 2.00Median Difference in GSK2531398 (M6) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
  • Part 1: Moderate Hepatic Impairment Participants vs Part 1: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.9837 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2531401 (M13) (Moderate hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 2: Tmax of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Reported as:
Median · Hours
Part 2: Tmax of GSK1278863 and Its Metabolites
HoursPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK12788631.50 (1.0 to 3.0)1.50 (1.0 to 4.0)
GSK2391220 (M2)3.00 (3.0 to 4.0)3.00 (2.0 to 4.0)
GSK2487818 (M4)3.00 (2.0 to 4.0)3.00 (2.0 to 4.0)
GSK2506102 (M5)3.50 (3.0 to 4.0)3.00 (2.0 to 6.0)
GSK2506104 (M3)3.50 (3.0 to 4.0)3.00 (2.0 to 6.0)
GSK2531398 (M6)3.00 (3.0 to 4.0)3.00 (2.0 to 6.0)
GSK2531401 (M13)4.00 (3.0 to 4.0)4.00 (3.0 to 6.0)
Statistical analysis
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.6224 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 0.50Median Difference in GSK1278863 (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.8042 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 0.00Median Difference in GSK2391220 (M2) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.8423 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2506104 (M3) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.5207 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2487818 (M4) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.8423 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2506102 (M5) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 1.0000 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI -1.00 to 1.00Median Difference in GSK2531398 (M6) (Mild hepatic impairment participants versus Healthy participants) has been presented.
  • Part 2: Mild Hepatic Impairment Participants vs Part 2: Healthy Participants · Wilcoxon (Mann-Whitney) · p = 0.8042 (P-value was based on Mann-Whitney U test (exact Wilcoxon rank sum test).) · Median difference (final values): 0.00 · 90% CI 0.00 to 1.00Median Difference in GSK2531401 (M13) (Mild hepatic impairment participants versus Healthy participants) has been presented.
PrimaryPart 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
3 hours, 12 hours and 24 hours post-dose
Reported as:
Mean · Nanograms per milliliter
Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites
Nanograms per milliliterPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK1278863; 3 hours0.27989 ± 0.2616680.11076 ± 0.070114
GSK1278863; 12 hoursNA ± NANA ± NA
GSK1278863; 24 hoursNA ± NANA ± NA
GSK2391220 (M2); 3 hours4.47750 ± 1.7794682.85875 ± 1.129961
GSK2391220 (M2); 12 hours0.76525 ± 0.6560870.22463 ± 0.119826
GSK2391220 (M2); 24 hours0.06460 ± 0.0892090.00963 ± 0.017963
GSK2487818 (M4); 3 hours3.24463 ± 1.5069641.86813 ± 0.760479
GSK2487818 (M4); 12 hours0.29301 ± 0.3387730.04769 ± 0.031411
GSK2487818 (M4); 24 hours0.01201 ± 0.023617NA ± NA
GSK2506102 (M5); 3 hours0.64588 ± 0.2423210.43175 ± 0.165059
GSK2506102 (M5); 12 hours0.13024 ± 0.1090890.04143 ± 0.031140
GSK2506102 (M5); 24 hours0.00923 ± 0.026092NA ± NA
GSK2506104 (M3); 3 hours3.86250 ± 1.4022412.57000 ± 1.010262
GSK2506104 (M3); 12 hours0.71075 ± 0.6014520.23938 ± 0.121781
GSK2506104 (M3); 24 hours0.06315 ± 0.1049940.00829 ± 0.015374
GSK2531398 (M6); 3 hours1.42725 ± 0.5522870.89338 ± 0.334179
GSK2531398 (M6); 12 hours0.22973 ± 0.1995140.06548 ± 0.035504
GSK2531398 (M6); 24 hours0.01470 ± 0.028580NA ± NA
GSK2531401 (M13); 3 hours2.25375 ± 0.6467712.03738 ± 0.807331
GSK2531401 (M13); 12 hours0.63125 ± 0.3798040.32075 ± 0.163981
GSK2531401 (M13); 24 hours0.07580 ± 0.1107380.01053 ± 0.020023
PrimaryPart 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
3 hours, 12 hours and 24 hours post-dose
Reported as:
Mean · Nanograms per milliliter
Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites
Nanograms per milliliterPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK1278863; 3 hours; n=6, 61.24213 ± 2.4753470.15692 ± 0.138726
GSK1278863; 12 hours; n=7, 60.04343 ± 0.1149010.01527 ± 0.037396
GSK1278863; 24 hours; n=7, 6NA ± NANA ± NA
GSK2391220 (M2); 3 hours; n=8, 75.32625 ± 2.1394722.13700 ± 1.276959
GSK2391220 (M2); 12 hours; n=8, 70.81263 ± 0.6000310.24371 ± 0.079803
GSK2391220 (M2); 24 hours; n=8, 70.30654 ± 0.729605NA ± NA
GSK2487818 (M4); 3 hours; n=8,73.91375 ± 1.4412191.57633 ± 0.937244
GSK2487818 (M4); 12 hours; n=8,70.40141 ± 0.5606380.07793 ± 0.033300
GSK2487818 (M4); 24 hours; n=8,70.00839 ± 0.0155860.00454 ± 0.012019
GSK2506102 (M5); 3 hours; n=8,70.78213 ± 0.3141770.31091 ± 0.213793
GSK2506102 (M5); 12 hours; n=8,70.25856 ± 0.4257590.04796 ± 0.035510
GSK2506102 (M5); 24 hours; n=8,7NA ± NANA ± NA
GSK2506104 (M3); 3 hours; n=8,74.68625 ± 1.8398831.94271 ± 1.262970
GSK2506104 (M3); 12 hours; n=8,70.75350 ± 0.4966380.27014 ± 0.122830
GSK2506104 (M3); 24 hours; n=8,70.04093 ± 0.0294450.00819 ± 0.021657
GSK2531398 (M6); 3 hours; n=8,71.86763 ± 0.7139580.73530 ± 0.451869
GSK2531398 (M6); 12 hours; n=8,70.34200 ± 0.4125050.07879 ± 0.023474
GSK2531398 (M6); 24 hours; n=8,7NA ± NANA ± NA
GSK2531401 (M13); 3 hours; n=8,72.47825 ± 0.9659441.26771 ± 0.871839
GSK2531401 (M13); 12 hours; n=8,70.75363 ± 0.5972070.29429 ± 0.153615
GSK2531401 (M13); 24 hours; n=8,70.29830 ± 0.7209190.00454 ± 0.012019
PrimaryPart 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.

Time frame:
3 hours, 12 hours and 24 hours post-dose
Reported as:
Mean · Percentage of unbound drug in plasma
Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites
Percentage of unbound drug in plasmaPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
GSK1278863; 3 hours; n=8, 80.0034 ± 0.001090.0028 ± 0.00019
GSK1278863; 12 hours; n=8, 8NA ± NANA ± NA
GSK1278863; 24 hours; n=8,8NA ± NANA ± NA
GSK2391220 (M2); 3 hours; n=8,80.3379 ± 0.035730.3495 ± 0.05135
GSK2391220 (M2); 12 hours; n=8,80.3540 ± 0.021860.3355 ± 0.02172
GSK2391220 (M2); 24 hours; n=4,20.3861 ± 0.028270.3902 ± 0.07149
GSK2487818 (M4); 3 hours; n=8,80.3080 ± 0.030850.2925 ± 0.01981
GSK2487818 (M4); 12 hours; n=8,70.3071 ± 0.034190.2402 ± 0.02431
GSK2487818 (M4); 24 hours; n=2,80.3508 ± 0.00191NA ± NA
GSK2506102 (M5); 3 hours; n=8, 80.2565 ± 0.045730.2441 ± 0.03397
GSK2506102 (M5); 12 hours; n=8, 60.2517 ± 0.040220.2335 ± 0.02679
GSK2506102 (M5); 24 hours; n=1, 80.2723 ± NANA ± NA
GSK2506104 (M3); 3 hours; n=8, 8NA ± NANA ± NA
GSK2506104 (M3); 12 hours; n=8, 8NA ± NANA ± NA
GSK2506104 (M3); 24 hours; n=8, 8NA ± NANA ± NA
GSK2531398 (M6); 3 hours; n=8, 80.2469 ± 0.043150.2461 ± 0.03264
GSK2531398 (M6); 12 hours; n=8, 80.2550 ± 0.031660.2295 ± 0.01509
GSK2531398 (M6); 24 hours; n=2, 80.3005 ± 0.03734NA ± NA
GSK2531401 (M13); 3 hours; n=8, 80.3519 ± 0.044310.3844 ± 0.06838
GSK2531401 (M13); 12 hours; n=8, 80.3771 ± 0.021140.3565 ± 0.02558
GSK2531401 (M13); 24 hours; n=6, 20.3817 ± 0.044490.3716 ± 0.02411
PrimaryPart 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.

Time frame:
3 hours, 12 hours and 24 hours post-dose
Reported as:
Mean · Percentage of unbound drug in plasma
Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites
Percentage of unbound drug in plasmaPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
GSK1278863; 3 hours; n=6, 60.0134 ± 0.023690.0032 ± 0.00090
GSK1278863; 12 hours; n=1, 10.1231 ± NA0.1246 ± NA
GSK1278863; 24 hours; n=8,7NA ± NANA ± NA
GSK2391220 (M2); 3 hours; n=8, 70.3191 ± 0.022630.3343 ± 0.06101
GSK2391220 (M2); 12 hours; n=7, 70.3305 ± 0.034970.3174 ± 0.02174
GSK2391220 (M2); 24 hours; n=5, 70.4099 ± 0.04797NA ± NA
GSK2487818 (M4); 3 hours; n=8, 70.2762 ± 0.027920.2857 ± 0.03897
GSK2487818 (M4); 12 hours; n=7, 70.2850 ± 0.031100.2766 ± 0.03608
GSK2487818 (M4); 24 hours; n=2, 10.3116 ± 0.071060.3387 ± NA
GSK2506102 (M5); 3 hours; n=8, 60.2339 ± 0.027040.2171 ± 0.06728
GSK2506102 (M5); 12 hours; n=7, 60.2483 ± 0.031660.2191 ± 0.02903
GSK2506102 (M5); 24 hours; n=8, 7NA ± NANA ± NA
GSK2506104 (M3); 3 hours; n=8, 70.2904 ± 0.024800.2938 ± 0.02618
GSK2506104 (M3); 12 hours; n=7, 70.2970 ± 0.029590.2845 ± 0.02193
GSK2506104 (M3); 24 hours; n=6, 10.3267 ± 0.031710.3016 ± NA
GSK2531398 (M6); 3 hours; n=8, 70.2491 ± 0.029890.2444 ± 0.04833
GSK2531398 (M6); 12 hours; n=7, 70.2500 ± 0.032590.2346 ± 0.02031
GSK2531398 (M6); 24 hours; n=8, 7NA ± NANA ± NA
GSK2531401 (M13); 3 hours; n=8, 70.3595 ± 0.023240.3569 ± 0.03504
GSK2531401 (M13); 12 hours; n=7, 70.3527 ± 0.039570.3386 ± 0.01580
GSK2531401 (M13); 24 hours; n=5, 10.4154 ± 0.031510.3845 ± NA
SecondaryPart 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863

Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Mean · International units per liter
Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863
International units per literPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK127886348.898 ± 36.847628.391 ± 13.1904
SecondaryPart 2: Cmax, EPO Following Administration of GSK1278863

Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Mean · International units per liter
Part 2: Cmax, EPO Following Administration of GSK1278863
International units per literPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Part 2: Cmax, EPO Following Administration of GSK127886343.933 ± 20.260245.871 ± 35.1537
SecondaryPart 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863

Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Median · Hours
Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863
HoursPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK127886310.0 (8 to 12)10.0 (8 to 10)
SecondaryPart 2: Tmax, EPO Following Administration of GSK1278863

Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Median · Hours
Part 2: Tmax, EPO Following Administration of GSK1278863
HoursPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Part 2: Tmax, EPO Following Administration of GSK127886310.0 (0 to 48)10.0 (6 to 12)
SecondaryPart 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863

Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Mean · Hours* International units per liter
Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863
Hours* International units per literPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK12788631262.3724 ± 1148.34702697.7140 ± 393.05978
SecondaryPart 2: AUC (0-t, EPO) Following Administration of GSK1278863

Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.

Time frame:
Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Reported as:
Mean · Hours* International units per liter
Part 2: AUC (0-t, EPO) Following Administration of GSK1278863
Hours* International units per literPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Part 2: AUC (0-t, EPO) Following Administration of GSK12788631258.6211 ± 683.328481061.7549 ± 647.67154
SecondaryPart 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.

Time frame:
Up to 16 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
Any SAE00
Any AE12
SecondaryPart 2: Number of Participants With AEs and SAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.

Time frame:
Up to 16 days
Reported as:
Count of participants · Participants
Part 2: Number of Participants With AEs and SAEs
ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Any SAE00
Any AE00
SecondaryPart 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 grams per liter (g/L) for hemoglobin, \<3 or \>20 x10\^9 cells per liter (cells/L) for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given \[e.g.\], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

Time frame:
Baseline (Screening) and up to Day 16
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
ParticipantsPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
Hematocrit; To Low00
Hematocrit; To within Range or No Change88
Hematocrit; To High00
Hemoglobin; To Low00
Hemoglobin; To within Range or No Change88
Hemoglobin; To High00
Leukocytes; To Low10
Leukocytes; To within Range or No Change78
Leukocytes; To High00
Lymphocytes; To Low00
Lymphocytes; To within Range or No Change88
Lymphocytes; To High00
Neutrophils; To Low00
Neutrophils; To within Range or No Change88
Neutrophils; To High00
Platelets; To Low00
Platelets; To within Range or No Change88
Platelets; To High00
SecondaryPart 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 g/L for hemoglobin, \<3 or \>20 x10\^9 cells/L for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

Time frame:
Baseline (Screening) and up to Day 16
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline
ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Hematocrit; To Low00
Hematocrit; To within Range or No Change129
Hematocrit; To High00
Hemoglobin; To Low00
Hemoglobin; To within Range or No Change129
Hemoglobin; To High00
Leukocytes; To Low00
Leukocytes; To within Range or No Change129
Leukocytes; To High00
Lymphocytes; To Low10
Lymphocytes; To within Range or No Change119
Lymphocytes; To High00
Neutrophils; To Low00
Neutrophils; To within Range or No Change129
Neutrophils; To High00
Platelets; To Low00
Platelets; To within Range or No Change129
Platelets; To High00
SecondaryPart 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 millimoles/L(mmol/L) (calcium), \<3 or \>9mmol/L(glucose), \>=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase \[ALT\]), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L(aspartate aminotransferase \[AST\]), \>=1.5 times ULN micromoles/L (µmol/L)(bilirubin), \<3 or \>5.5mmol/L(potassium), and \<130 or \>150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

Time frame:
Baseline (Screening) and up to Day 16
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline
ParticipantsPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
ALT ; To Low00
ALT;To within Range or No Change88
ALT; To High00
Albumin; To Low00
Albumin; To within Range or No Change88
Albumin; To High00
Alkaline Phosphatase; To Low00
Alkaline Phosphatase; To within Range or No Change88
Alkaline Phosphatase; To High00
AST; To Low00
AST;To within Range or No Change88
AST; To High00
Bilirubin; To Low00
Bilirubin; To within Range or No Change88
Bilirubin; To High00
Calcium; To Low00
Calcium; To within Range or No Change88
Calcium; To High00
Glucose; To Low00
Glucose; To within Range or No Change68
Glucose; To High20
Potassium; To Low00
Potassium; To within Range or No Change88
Potassium; To High00
Sodium; To Low10
Sodium; To within Range or No Change78
Sodium; To High00
SecondaryPart 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 mmol/L (calcium), \<3 or \>9mmol/L (glucose), \>=2 times ULN U/L (ALT), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L (AST), \>=1.5 times ULN µmol/L (bilirubin), \<3 or \>5.5 mmol/L (potassium), and \<130 or \>150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.

Time frame:
Baseline (Screening) and up to Day 16
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline
ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
ALT ; To Low00
ALT;To within Range or No Change129
ALT ; To High00
Albumin; To Low00
Albumin; To within Range or No Change129
Albumin; To High00
Alkaline Phosphatase; To Low00
Alkaline Phosphatase; To within Range or No Change129
Alkaline Phosphatase; To High00
AST; To Low00
AST;To within Range or No Change129
AST; To High00
Bilirubin; To Low00
Bilirubin; To within Range or No Change129
Bilirubin; To High00
Calcium; To Low00
Calcium; To within Range or No Change129
Calcium; To High00
Glucose; To Low00
Glucose; To within Range or No Change109
Glucose; To High20
Potassium; To Low00
Potassium; To within Range or No Change129
Potassium; To High00
Sodium; To Low00
Sodium; To within Range or No Change129
Sodium; To High00
SecondaryPart 1: Number of Participants With Abnormal Urinalysis Findings

Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.

Time frame:
Up to Day 16
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Urinalysis Findings
ParticipantsPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy Participants
Part 1: Number of Participants With Abnormal Urinalysis Findings00
SecondaryPart 2: Number of Participants With Abnormal Urinalysis Findings

Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.

Time frame:
Up to Day 16
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Urinalysis Findings
ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
Part 2: Number of Participants With Abnormal Urinalysis Findings00

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 16 days in each part of the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Moderate Hepatic Impairment Participants0/8 (0%)0/8 (0%)1/8 (12.5%)
Part 1: Healthy Participants0/8 (0%)0/8 (0%)2/8 (25%)
Part 2: Mild Hepatic Impairment Participants0/12 (0%)0/12 (0%)0/12 (0%)
Part 2: Healthy Participants0/9 (0%)0/9 (0%)0/9 (0%)
Most frequent other events
Most frequent other events
EventPart 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy Participants
ToothacheGastrointestinal disorders0/81/80/120/9
Upper respiratory tract infectionInfections and infestations0/81/80/120/9
Skin abrasionInjury, poisoning and procedural complications1/80/80/120/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy ParticipantsTotal
Mean59.5 ± 6.0057.6 ± 7.1561.9 ± 7.5558.7 ± 8.0359.7 ± 7.18
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy ParticipantsTotal
Female11226
Male7710731
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Moderate Hepatic Impairment ParticipantsPart 1: Healthy ParticipantsPart 2: Mild Hepatic Impairment ParticipantsPart 2: Healthy ParticipantsTotal
BLACK OR AFRICAN AMERICAN02125
WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE866626
ASIAN - EAST ASIAN HERITAGE00101
WHITE - ARABIC/NORTH AFRICAN HERITAGE00415
08

Study locations

2 sites
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
09

References and documents

Publications

  • Mahar KM, Shaddinger BC, Ramanjineyulu B, Andrews S, Caltabiano S, Lindsay AC, Cobitz AR. Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function. Clin Pharmacol Drug Dev. 2022 May;11(5):562-575. doi: 10.1002/cpdd.1090. Epub 2022 Mar 30. PubMed 35355447 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Aug 2018, 12 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 12 months is above that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2017
First posted
Jul 21, 2017
StartActual
Jul 24, 2017
Primary completionActual
Aug 20, 2018
CompletionActual
Aug 20, 2018
Results first posted
Sep 4, 2019
Last update
Sep 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03223337
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Jul 24, 2017
Primary completion
Aug 20, 2018
Completion
Aug 20, 2018
Results posted
Sep 4, 2019
Last update
Sep 4, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion